SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

A recent $75 million direct offering to an undisclosed institutional investor, coupled with a notable increase in Vanguard's stake, has Altimmune driving vigorous community debate over whether this development validates its 'best-in-class' MASH drug for a strategic partnership or reflects a costly dilution to fund upcoming Phase 3 preparations.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is seeing heightened attention amidst investor debate over Google's new AI-powered game creation tool, which some fear could disrupt its sector, while others dismiss the threat, all against a backdrop of ongoing child safety concerns and an anticipated earnings report.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital Corp is trending after reporting significantly missed earnings, announcing a 50% dividend cut, and hitting a new 52-week low on heavy volume, fueling widespread community outrage over management and concerns about the CLO market's impact.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

BNB is trending as Binance converts $1 billion of its reserves into Bitcoin and its former CEO CZ receives a presidential pardon, which is prompting community discussion about the implications for Binance's leadership and regulatory environment. Amid concerns over recent large outflows from the exchange, the community is also observing BNB Chain's continued expansion into institutional services and real-world asset tokenization.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver Corporation is trending as silver prices continue to surge and command significant premiums in physical markets, with the community actively discussing potential market manipulation suppressing paper prices. Many investors view recent volatility and miner underperformance as a prime opportunity to acquire shares ahead of anticipated strong earnings, believing the broader silver bull market is poised for further expansion.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is gaining attention from recent DOE agreements for its Integral Molten Salt Reactor pilot programs and fuel production, alongside new analyst coverage with a $15 price target. The community actively discusses IMSR's potential as a key Gen-IV nuclear energy solution, particularly for the surging power demands of AI data centers.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending amidst a significant market downturn following Google DeepMind's announcement of its AI-powered Genie 3 world model, which generates 3D interactive environments from text prompts. The community is sharply divided, with some fearing obsolescence for traditional game engines while others view the news as an overblown reaction and a prime buying opportunity, believing the new AI tool could ultimately benefit Unity's development platform.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as a key competitor ends its aggressive price war, fueling investor optimism for significantly improved profit margins, while the community debates whether this, alongside rapid store expansion, will finally unlock appreciation for the undervalued, OTC-listed stock.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Anticipation is high for Super Micro Computer's upcoming Q2 earnings, with investors debating potential massive revenue growth driven by surging AI demand against persistent concerns over razor-thin margins. The community is highly polarized, with calls for a short squeeze contrasting fears of continued management and execution challenges.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending as technical analysis highlights a potential bullish reversal with a double-bottom pattern and significant whale accumulation, while increasing activity on Shibarium is fueling community anticipation for a breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

ELV tops Q4 EPS estimates as premiums grow and Carelon revenues surge, even as medical membership slips and expenses climb.

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

CNC teams up with Tuesday Health to expand palliative care in Ohio, blending in-person and virtual support.

Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy

Zacks Research upgraded shares of Fortress Biotech from a "hold" rating to a "strong-buy" rating in a research report on Wednesday...

Research Analysts Set Expectations for FBIO FY2025 Earnings

Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) - Stock analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Fortress Biotech in a research report issued to...

Morning Market Brief: From IP Land Grabs to FDA Greenlights, Small-Cap Innovation Takes Center Stage

<ul class="summary-bullets"><li>The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for developing and commercializing CUTX-101.</li><li>Cyprium stands to earn tiered royalties on ZYCUBO sales and up to $129 million in potential development and sales milestones from Sentynl.</li><li>Children receiving early treatment with ZYCUBO had a nearly 80% lower risk of death compared with untreated patients.&nbsp;</li></ul>Fortress Biotech, Inc. (FBIO) and its majority-owned unit, Cyprium Therapeutics, announced on Tuesday that the U.S. Food and Drug Administration (FDA) has officially approved ZYCUBO (formerly CUTX-101) for treating Menkes disease in children.The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for developing and commercializing CUTX-101 from Cyprium in December 2023.<blockquote>“The approval of ZYCUBO is a pivotal milestone for our company and patients suffering from Menkes Disease, as it is the first and only FDA-approved treatment for this rare, often fatal, pediatric disease.”-Lindsay A. Rosenwald, Chairman, President and CEO, Fortress Biotech</blockquote><h2 class="st-heading-2">Approval And Benefits</h2>The approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium. Additionally, Cyprium stands to earn tiered royalties on ZYCUBO sales and up to $129 million in potential development and sales milestones from Sentynl.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/FBIO">Fortress Biotech stock</a> traded over 12% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_13_083353_png_10f3be8db7.webp" alt="FBIO’s Sentiment Meter and Message Volume as of 07:40 a.m. ET on Jan. 13, 2026 | Source: Stocktwits" width="927" height="102"><figcaption>FBIO’s Sentiment Meter and Message Volume as of 07:40 a.m. ET on Jan. 13, 2026 | Source: Stocktwits</figcaption></figure>Menkes disease is a rare genetic disorder caused by mutations in the ATP7A gene, which disrupt copper absorption and transport in infants. Without treatment, the disease can be fatal, as copper is essential for brain development.&nbsp;<h2 class="st-heading-2">ZYCUBO Efficiency&nbsp;</h2>ZYCUBO, administered as a subcutaneous injection, helps restore copper balance in the body and maintain adequate levels in patients with Menkes disease.Results supporting approval showed that children receiving early treatment with ZYCUBO had a nearly 80% lower risk of death compared with untreated patients. Median overall survival in the treated group was 177.1 months, compared with 17.6 months in the external control group.&nbsp;FBIO stock has gained over 113% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/delta-airlines-stock-falls-2026-guidance-boeing-order/cmUXI2vR44s">Delta Air Lines Stock Tumbles Despite Q4 Earnings Beat – Even A Boeing Order Failed To Lift Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Fortress Biotech logo is displayed on the screen of a tablet.

FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease

FDA’s ZYCUBO approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium.

Equity

FDA’s ZYCUBO approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium.


Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200 Day Moving Average - Should You Sell...

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average - Here's Why...

Envestnet Asset Management Inc. Sells 98,195 Shares of Fortress Biotech, Inc. $FBIO

Envestnet Asset Management Inc. lessened its holdings in Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) by 36.7% during the second quarter, according to its most recent 13F filing with the...

Fortress Biotech (NASDAQ:FBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded Fortress Biotech from a "hold" rating to a "buy" rating in a report on Sunday...

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

FBIO
Fortress Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FBIO News

FBIOFortress Biotech Inc